课题基金 / 基金详情

Brain-specific enzyme cholesterol 24-hydroxylase (Cyp46A1) as a novel therapeutic target in human prion diseases

Brain-specific enzyme cholesterol 24-hydroxylase (Cyp46A1) as a novel therapeutic target in human prion diseases
脑特异性酶胆固醇 24-羟化酶 (Cyp46A1) 作为人类朊病毒疾病的新型治疗靶点
批准号：
440680
负责人：
Ali Tahir
金额：
$9.83万
依托单位：
University of Calgary
依托单位国家：
加拿大
项目类别：
Fellowship Programs
财政年份：
2020
资助国家：
加拿大
项目状态：
已结题
起止时间：
2020-12-01 至 2023-12-01
来源：
https://webapps.cihr-irsc.gc.ca/decisions/p/project_details.html?applId=440680&lang=en
关键词：
Brain Cholesterol Metabolism Cellular Models Of Prion Diseases Cholesterol 24-Hydroxylase (Cyp46a1) Cyp46a1 Activator (Efavirenz) Fda-Approved Repurposed Drug (Efavirenz) Human Prion Diseases Mouse Models Of Human Prion Diseases Neurodegenerative D

项目摘要

项目成果

Ali Tahir的其他基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
Prion diseases are infectious and fatal neurodegenerative disorders that affect humans and animals. Creutzfeldt-Jakob disease (CJD) is the most common human prion disease. Animal prion diseases include scrapie in sheep/goat and mad cow disease which has b
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
Regulation of the brain-specific cholesterol hydroxylase Cyp46A1 as a novel approach for the treatment of prion diseases
  • 批准号：
    454456
  • 项目类别：
    Fellowship Programs
  • 资助金额：
    $3.28万
  • 财政年份：
    2021
  • 负责人：
    Ali Tahir
  • 依托单位：
    University of Calgary
Cyp46A1 as a novel therapeutic target in prion diseases
  • 批准号：
    436100
  • 项目类别：
    Fellowship Programs
  • 资助金额：
    $10.2万
  • 财政年份：
    2020
  • 负责人：
    Ali Tahir
  • 依托单位：
    University of Calgary